On the other hand, for ALK-rearranged tumours, the interim analysis of the ALNEO-GOIRC-01-2020 phase II trial in resectable stage III ALK-positive NSCLC reported that 8 weeks of neoadjuvant alectinib plus 96 weeks of adjuvant treatment resulted in an ORR of 68%, an MPR rate of 38.9%, and a pCR rate of 17%, supporting future developments in this setting [44]. Here, ALK is linked to non-small cell lung carcinoma.